The invention is directed to antibacterial compositions comprising bacteria modified to comprise phasmids engineered to deliver of CRISPR RNAs and methods for their use.

The present disclosure is directed to materials and methods for reducing heterologous DNA damage in bacteria (i.e., induce resistance to host restriction enzymes) by modifying the heterologous DNA to include one or more deazapurine bases.

A method of recovering viable phage from, for example, a crude phage preparation such as a lysate resulting from amplification of phage in bacterial cell culture is disclosed. The method may be “universal”; that is, applicable to the purification of a broad range of phage species and strains. The phage product resulting from the method may have an acceptably low endotoxin titer (e.g. less than 500 EU/ml) and sufficiently high phage titer (e.g. >1×10.sup.9 PFU/ml) for use in therapeutic applications.

The present invention related to a method for producing or propagating an engineered bacteriophage, comprising the steps of: providing a functional synthetic genome of an engineered bacteriophage being able to infect a target bacterium; providing a recipient bacterium; transforming the recipient bacterium with the functional synthetic genome in a transformation step, yielding a transformed recipient bacterium; incubating the transformed recipient bacterium in a first incubation step, wherein the engineered bacteriophage is propagated within the transformed recipient bacterium; and further incubating the transformed recipient bacterium or the propagated engineered bacteriophage released from the transformed recipient bacterium with the target bacterium in a second incubation step, wherein the propagated engineered bacteriophage infects the target bacterium and is further propagated within the target bacterium, and wherein the recipient bacterium is a cell wall-deficient bacterium.

A method of recovering viable phage from, for example, a crude phage preparation such as a lysate resulting from amplification of phage in bacterial cell culture is disclosed. The method may be universal; that is, applicable to the purification of a broad range of phage species and strains. The phage product resulting from the method may have an acceptably low endotoxin titer (e.g. less than 500 EU/ml) and sufficiently high phage titer (e.g. >1?10.sup.9 PFU/ml) for use in therapeutic applications.

The invention is directed to antibacterial compositions comprising bacteria modified to comprise phasmids engineered to deliver of CRISPR RNAs and methods for their use.

A method of recovering viable phage from, for example, a crude phage preparation such as a lysate resulting from amplification of phage in bacterial cell culture is disclosed. The method may be universal; that is, applicable to the purification of a broad range of phage species and strains. The phage product resulting from the method may have an acceptably low endotoxin titer (e.g. less than 500 EU/ml) and sufficiently high phage titer (e.g. >1?10.sup.9 PFU/ml) for use in therapeutic applications.

The present invention relates to a genetically modified phage and use thereof in a method for producing a biomolecule of interest.

A method of manufacturing of a dry mixture of at least one yeast and/or yeast derivative and at least one bacteriophage, where the mixture being in the form of solid entities, and each solid entity is composed of at least one yeast and/or at least one yeast derivative and at least one bacteriophage and possibly at least one drying excipient, where the method is done by the mixing of at least one yeast and/or yeast derivative and at least one bacteriophage in suspension and the drying of this mixture. Also, a dry mixture of at least one yeast and/or yeast derivative and at least one bacteriophage, which is in the form of solid entities, where each solid entity is composed of at least one yeast and/or at least one yeast derivative and at least one bacteriophage and possibly at least one drying excipient and uses thereof.

Bacteriophage are disclosed herein that include a head, a tail, and a lambda genome comprising a nucleic acid sequence encoding a fusion protein comprising a D protein linked to heterologous antigen, wherein the nucleic acid sequence is inserted into a native gene D locus adjacent to gene E, in the lambda genome, and wherein expression of the fusion protein results in the head of the bacteriophage comprising the fusion protein. Host bacterial cells also disclosed herein that are infected with the bacteriophage . In addition, immunogenic compositions are disclosed that include an effective amount of the bacteriophage . Methods also are disclosed for inducing an immune response to the heterologous antigen in a subject. Furthermore, methods are disclosed for preparing these bacteriophage .